Immunomedics, Inc. (IMMU.W)
3.39USD
2 Feb 2010
$0.16 (+5.44%)
$3.39
--
$3.10
$2.92
1,735,026
1,879,911
$7.16
$0.84
IMMU.W
About
Overall
| Beta: | 2.08 |
| Market Cap (Mil.): | $233.31 |
| Shares Outstanding (Mil.): | 75.26 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| IMMU.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 6.95 | 11.50 | 3.76 |
| EPS (TTM): | 331.92 | -- | -- |
| ROI: | 100.31 | 1.25 | 2.30 |
| ROE: | 192.79 | 2.09 | 2.82 |
Immunomedics shares jump on patent for lupus drug
(Reuters) - Shares of biopharmaceutical company Immunomedics Inc rose as much as 45 percent after it said its experimental lupus drug received a U.S. patent.
UPDATE 1-Immunomedics posts quarterly profit
Aug 27 (Reuters) - Immunomedics Inc posted a quarterly profit on collaboration revenue and said it expects cash expenditures in 2010 to be at a higher level to support an "aggressive" clinical development agenda.
HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 27
(Updates to afternoon trading, adds Geron, OSI Systems, OshKosh, NCI Building, Immunomedics, Precision Castparts, TiVo, Jackson Hewitt, A-Power, Whiting and Gerber)
UPDATE 3-Immunomedics soars as lupus drug shows promise
* Treatment advantage of epratuzumab vs placebo 24.9 pct
UPDATE 3-Human Genome lupus trial success is classic biotech
* Success of drug shocks previously skeptical Wall Street
Human Genome lupus drug success is classic biotech
BOSTON (Reuters) - Human Genome Sciences Inc said on Monday that its experimental lupus drug succeeded in a late-stage clinical trial, shocking many who had written the product off, and sending the stock up more than 200 percent.
UPDATE 3-Human Genome lupus drug success is classic biotech
* Drug filing expected with FDA by early next year (Updates with background, detail, analysis)
UPDATE 1-Immunomedics in license deal with Nycomed; shares rise
July 14 (Reuters) - Immunomedics Inc said it entered into a licensing agreement with Swiss drug company Nycomed to develop and market veltuzumab, its experimental anti-body for non-cancer indications.
Immunomedics Q1 results
IMMUNOMEDICS INC : * First quarter loss per share $0.06 * First quarter revenue $800,000 * Reuters Estimates first quarter loss per share view $0.08, revenue view $0.89 million
Competitors
| Price | Change | |
|---|---|---|
| Biogen Idec Inc. (BIIB.OQ) | $54.09 | +1.25 |
| Genentech, Inc. (DNA.N) | -- | -- |
| GlaxoSmithKline plc (GSK.L) | £1,206.00 | -12.50 |
| Roche Holding Ltd. (ROG.VX) | CHF176.20 | +0.10 |
| Human Genome Sciences (HGSI.OQ) | $27.06 | +1.30 |
| Seattle Genetics, Inc. (SGEN.OQ) | $9.59 | +0.25 |
| Trubion Pharmaceuticals, Inc. (TRBN.OQ) | $3.90 | +0.71 |
| ZymoGenetics, Inc. (ZGEN.OQ) | $5.05 | -0.07 |
| Merck & Co., Inc. (MRK.N) | $36.47 | -0.12 |
| Genmab A/S (GEN.CO) | kr.93.20 | -0.75 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
